JPRN-UMIN000015496招募中1 期
Phase I/II trial of paclitaxeal and cisplatin in patients with recurrent ovarian cancer - Phase I/II trial of paclitaxeal and cisplatin in patients with recurrent ovarian cancer
SchooMedicine, Chiba university0 个研究点目标入组 30 人开始时间: 2014年10月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients who have a history of hypersensitivity to paclitaxeal. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
研究者
相似试验
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
已完成
不适用
Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer.Squamous cell lung cancerJPRN-UMIN000008872Tochigi Cancer Center17
进行中（未招募）
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004651-23-FRInstitut Jules Bordet180
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209
招募中
2 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer2024-511850-34-00Institut Jules Bordet209